SEC (Securities and Exchange Commission) warns Lumenis over likely legal action
This article was originally published in Clinica
The US Securities and Exchange Commission (SEC) has sent Yokneam, Israel-based Lumenis a Wells Notice, indicating that it may be preparing civil proceedings against the laser therapy firm. The move comes as part of an investigation by the SEC's Boston district office into Lumenis's accounts. Lumenis will now have time to discuss the issues with the SEC before the latter decides what action to take.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.